Financials Vicarious Surgical Inc.
Equities
RBOT
US92561V2088
Advanced Medical Equipment & Technology
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
6.91 USD | +5.34% |
|
+3.60% | -37.19% |
Apr. 29 | Transcript : Vicarious Surgical Inc., Q1 2024 Earnings Call, Apr 29, 2024 | |
Apr. 29 | Vicarious Surgical Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Valuation
Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|
Capitalization 1 | - | 1,260 | 247.2 | 64.13 | 40.63 | - | - |
Enterprise Value (EV) 1 | - | 1,088 | 247.2 | -19.21 | 4.029 | -30.19 | 25.39 |
P/E ratio | -4.58 x | -177 x | 50.5 x | -0.75 x | -0.61 x | -0.54 x | -0.54 x |
Yield | - | - | - | - | - | - | - |
Capitalization / Revenue | - | - | - | - | - | - | - |
EV / Revenue | - | - | - | - | - | - | - |
EV / EBITDA | - | -31.8 x | -3.13 x | 0.24 x | -0.07 x | 0.47 x | -0.38 x |
EV / FCF | - | -31,445,321 x | - | - | - | - | - |
FCF Yield | - | -0% | - | - | - | - | - |
Price to Book | - | 15.3 x | - | 0.66 x | 0.85 x | 0.68 x | 2.3 x |
Nbr of stocks (in thousands) | - | 3,954 | 4,079 | 5,830 | 5,879 | - | - |
Reference price 2 | 304.8 | 318.6 | 60.60 | 11.00 | 6.910 | 6.910 | 6.910 |
Announcement Date | 6/11/21 | 3/3/22 | 2/13/23 | 3/4/24 | - | - | - |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|
Net sales 1 | - | - | - | - | - | - | - |
EBITDA 1 | - | -34.21 | -78.97 | -78.81 | -60.58 | -64.55 | -67.23 |
EBIT 1 | - | -38.57 | -80.08 | -80.67 | -66.22 | -73.99 | -78.78 |
Operating Margin | - | - | - | - | - | - | - |
Earnings before Tax (EBT) 1 | - | -7.268 | 5.157 | -71.07 | -70.15 | -79.1 | -82.9 |
Net income 1 | -12.88 | -7.268 | 5.157 | -71.07 | -66.67 | -75.23 | -78.93 |
Net margin | - | - | - | - | - | - | - |
EPS 2 | -66.60 | -1.800 | 1.200 | -14.70 | -11.30 | -12.70 | -12.70 |
Free Cash Flow | - | -34.59 | - | - | - | - | - |
FCF margin | - | - | - | - | - | - | - |
FCF Conversion (EBITDA) | - | - | - | - | - | - | - |
FCF Conversion (Net income) | - | - | - | - | - | - | - |
Dividend per Share | - | - | - | - | - | - | - |
Announcement Date | 6/11/21 | 3/3/22 | 2/13/23 | 3/4/24 | - | - | - |
Income Statement Evolution (Quarterly data)
Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net sales 1 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBITDA 1 | -14.99 | -18 | -18.94 | -21.82 | -20.21 | -21.87 | -21.02 | -20.9 | -15.02 | -15.59 | -15.1 | -15.8 | -15.1 | -20.05 | -20.15 |
EBIT 1 | -18.17 | -18.18 | -19.13 | -22.16 | -20.61 | -22.32 | -21.46 | -21.35 | -15.54 | -16.11 | -16.73 | -16.97 | -17.3 | -20.1 | -20.2 |
Operating Margin | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Earnings before Tax (EBT) 1 | 70.08 | 42.53 | -1.453 | -24.74 | -11.18 | -26.92 | -15.33 | -15.7 | -13.11 | -17 | -17.65 | -17.85 | -18.15 | -20.6 | -20.7 |
Net income 1 | 70.08 | 42.53 | -1.453 | -24.74 | -11.18 | -26.92 | -15.33 | -15.7 | -13.11 | -17 | -16.4 | -16.63 | -16.97 | -20.6 | -20.7 |
Net margin | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EPS 2 | 17.70 | 9.900 | -0.3000 | -6.000 | -2.700 | -6.300 | -3.600 | -3.000 | -1.800 | -3.000 | -2.800 | -2.800 | -2.900 | -3.600 | -3.600 |
Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Announcement Date | 3/3/22 | 5/9/22 | 8/8/22 | 11/7/22 | 2/13/23 | 5/8/23 | 7/27/23 | 11/13/23 | 3/4/24 | 4/29/24 | - | - | - | - | - |
Balance Sheet Analysis
Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|
Net Debt 1 | - | - | - | - | - | - | - |
Net Cash position 1 | - | 172 | - | 83.3 | 36.6 | 70.8 | 15.2 |
Leverage (Debt/EBITDA) | - | - | - | - | - | - | - |
Free Cash Flow | - | -34.6 | - | - | - | - | - |
ROE (net income / shareholders' equity) | - | -77.3% | - | -68% | -85.5% | -107% | -147% |
ROA (Net income/ Total Assets) | - | - | - | - | - | - | - |
Assets 1 | - | - | - | - | - | - | - |
Book Value Per Share 2 | - | 20.80 | - | 16.70 | 8.100 | 10.20 | 3.000 |
Cash Flow per Share | - | -10.30 | - | - | - | - | - |
Capex | - | 1.29 | - | - | - | - | - |
Capex / Sales | - | - | - | - | - | - | - |
Announcement Date | 6/11/21 | 3/3/22 | 2/13/23 | 3/4/24 | - | - | - |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-37.19% | 40.63M | |
+0.91% | 204B | |
+3.74% | 178B | |
+28.89% | 154B | |
+31.66% | 112B | |
+1.48% | 64.16B | |
+19.45% | 54.88B | |
-3.44% | 46.69B | |
-9.28% | 36.8B | |
-0.10% | 35.26B |
- Stock Market
- Equities
- RBOT Stock
- Financials Vicarious Surgical Inc.